NICE Single Technology Appraisal Guidance No 183 – Topotecan
for the treatment of recurrent and stage IVB cervical cancer
The web reference for the appraisal and other related documents
NHSScotland should note
1. Recommendations of NICE Single Technology Appraisals (STAs)
have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the SMC advice.
3. The Scottish Medicines Consortium (SMC) published a Statement
of Advice on this medication for this indication in December 2007.
This stated that:
Topotecan (Hycamtin®) is accepted for
restricted use within NHS Scotland in combination with cisplatin
for patients with carcinoma of the cervix recurrent after
radiotherapy and for patients with stage IVB disease. It is
restricted to patients who are cisplatin-naïve.
advice of the Scottish Medicines Consortium
4. There is no material difference between the recommendations
of the NICE STA and the SMC.
If you need further assistance, please contact Eleanor Brownlee
in the first instance (tel 0141 225 6873 or email firstname.lastname@example.org).
Published Date: 25 November 2009